Brentuximab vedotin
Cat. No.: IBDI-431730
Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma.
Product Details
| Target |
Antibody-Drug Conjugates (ADCs) | Apoptosis | TNF Receptor |
| Appearance |
Solid |
| SMILES |
[Brentuximab vedotin] |
| Purity |
98.00% |
Storage & Handling
| Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.
